SCHEMBL5478341

SCHEMBL5478341

COc1cc(C(=O)C=NO)ccc1OC(C)C

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.48
ALDH1A1 P00352 3/20 0.48
PDE4B Q07343 2/20 0.48
MAPK1 P28482 2/20 0.48
PDE4A P27815 1/20 0.48
PDE4C Q08493 1/20 0.48
PDE4D Q08499 1/20 0.48
ABCG2 Q9UNQ0 4/20 0.48
LMNA P02545 3/20 0.47
SMN1; SMN2 Q16637 2/20 0.46
NPC1 O15118 2/20 0.46
TP53 P04637 1/20 0.46
RAB9A P51151 1/20 0.46
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2C9 P11712 1/20 0.46
TSHR P16473 1/20 0.46
CYP2C19 P33261 1/20 0.46
POLB P06746 1/20 0.46
CA12 O43570 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4448762 0.88 ABCG2 (0.59) MAPTALDH1A1MAPK1ABCG2LMNA
SCHEMBL5456801 0.84 ABCG2 (0.51) MAPTALDH1A1PDE4BMAPK1PDE4A
SCHEMBL4409526 0.81 TSHR (0.63) MAPTALDH1A1ABCG2LMNASMN1; SMN2
SCHEMBL1015345 0.79 CA12 (0.73) MAPTALDH1A1MAPK1LMNASMN1; SMN2
SCHEMBL5466423 0.79 ALDH1A1 (0.56) MAPTALDH1A1PDE4BMAPK1LMNA
SCHEMBL24812339 0.77 MAPK1 (0.62) MAPTALDH1A1PDE4BMAPK1PDE4A
SCHEMBL6568018 0.77 MAPT (0.66) MAPTALDH1A1PDE4BMAPK1LMNA
SCHEMBL2567410 0.77 ALDH1A1 (0.53) MAPTALDH1A1PDE4BMAPK1PDE4A
SCHEMBL25139437 0.77 HIF1A (0.53) MAPTALDH1A1PDE4BMAPK1SMN1; SMN2
SCHEMBL5478335 0.77 MAPT (0.46) MAPTALDH1A1PDE4BMAPK1PDE4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070032477-A1 Pteridine derivatives useful for making pharmaceutical compositions 4 AZA BIOSCIENCE NV (BE) 2007-02-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070032477-A1 Pteridine derivatives useful for making pharmaceutical compositions TPMT, TYMS, TNF MAPT 919/4885ALDH1A1 1733/4885PDE4B 1696/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.